Matrix Metalloproteinase-9 (MMP-9, also known as gelatinase B) is a zinc-dependent endopeptidase that degrades components of the extracellular matrix and plays important roles in tissue remodeling, synaptic plasticity, and blood-brain barrier (BBB) function. Dysregulated MMP-9 activity contributes to neurodegeneration through BBB disruption, inflammatory cell migration, and abnormal protein processing. MMP-9 inhibitors represent a therapeutic approach to restore vascular and neuronal homeostasis. [1]
MMP-9 is encoded by the MMP9 gene. Key features include:
MMP-9 is normally expressed at low levels but is upregulated in response to inflammation, injury, and disease processes. [2]
MMP-9 inhibitors work through enzyme inhibition and BBB protection:
BBB Protection: MMP-9 degrades tight junction proteins (claudin-5, occludin), leading to BBB disruption. Inhibitors preserve barrier integrity. [3]
Extracellular Matrix Preservation: MMP-9 degrades basement membrane components; inhibition maintains structural support for neurons and blood vessels.
Inflammation Modulation: MMP-9 cleaves and activates pro-inflammatory cytokines (TNF-α, IL-1β); inhibition reduces inflammatory signaling.
Synaptic Protection: MMP-9 is involved in synaptic remodeling; dysregulated activity contributes to synaptic dysfunction.
MMP-9 inhibitors may benefit AD through:
MMP-9 inhibitors are relevant for PD:
MMP-9 inhibitors are in various stages:
| Compound | Development Stage | Notes |
|---|---|---|
| SB-3CT | Preclinical | Selective MMP-9 inhibitor |
| Prinomastat (AG-3340) | Discontinued (cancer) | Broad MMP inhibitor |
| ANDRO | Research compound | Natural product |
| MMPI-based designs | Preclinical | Improving selectivity |
| Property | Value |
|---|---|
| Target | MMP-9 (Matrix Metalloproteinase-9, Gelatinase B) |
| Drug Class | Matrix metalloproteinase inhibitor |
| Mechanism | Zinc-chelating or substrate mimic |
| Selectivity | Broader MMPs vs. selective |
Vafadar B, et al. MMP-9 in neurodegenerative diseases: pathogenetic role and therapeutic potential. J Neurochem. 2019. ↩︎
Kumar R, et al. Matrix metalloproteinases in Alzheimer's disease and Parkinson's disease. Ageing Res Rev. 2020. ↩︎
Mantuano E, et al. MMP-9 and blood-brain barrier disruption in neurodegeneration. Brain. 2021. ↩︎